Zelira Therapeutics Ltd Market Cap ($4.65 Million)
Market Cap & Net Worth: Zelira Therapeutics Ltd (ZLD)
Zelira Therapeutics Ltd market cap. Zelira Therapeutics Ltd (AU:ZLD) has a market capitalization of $4.65 Million (AU$6.57 Million) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28644 globally and #1517 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zelira Therapeutics Ltd's stock price AU$0.50 by its total outstanding shares 13147155 (13.15 Million). Also see Zelira Therapeutics Ltd (ZLD) cash flow conversion for how efficiently the company converts equity into cash flow.
Zelira Therapeutics Ltd Market Cap History (2015–2026)
Zelira Therapeutics Ltd market cap history from 2015 to 2026. Data shows change from $32.56 Million to $4.65 Million (-17.84% CAGR). Check Zelira Therapeutics Ltd share price for real-time trading data and today's change.
Zelira Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zelira Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Zelira Therapeutics Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6026.74x
Zelira Therapeutics Ltd's market cap is 6026.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $63.49 Million | $2.73K | -$898.64K | 23256.12x | N/A |
| 2017 | $151.40 Million | $167.76K | -$6.16 Million | 902.46x | N/A |
| 2018 | $84.65 Million | $561.39K | -$1.73 Million | 150.79x | N/A |
| 2019 | $89.54 Million | $859.17K | -$2.90 Million | 104.21x | N/A |
| 2020 | $149.77 Million | $663.32K | -$7.02 Million | 225.79x | N/A |
| 2021 | $53.72 Million | $663.32K | -$8.55 Million | 80.99x | N/A |
| 2022 | $9.30 Million | $1.54 Million | -$11.95 Million | 6.04x | N/A |
| 2023 | $8.37 Million | $301.12K | -$5.57 Million | 27.80x | N/A |
| 2024 | $5.77 Million | $94.95K | -$36.57 Million | 60.74x | N/A |
| 2025 | $3.95 Million | $656.00 | -$3.63 Million | 6026.74x | N/A |
Competitor Companies of ZLD by Market Capitalization
Companies near Zelira Therapeutics Ltd in the global market cap rankings as of November 8, 2026. Also see ZLD current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Zelira Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Zelira Therapeutics Ltd (2015–2026)
Market capitalization of Zelira Therapeutics Ltd from 2015 to today. Between 2015 and today, Zelira Therapeutics Ltd's market cap moved from $32.56 Million to $ 4.65 Million, with a yearly change of -17.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$4.65 Million | +17.65% |
| 2025 | AU$3.95 Million | -31.45% |
| 2024 | AU$5.77 Million | -31.11% |
| 2023 | AU$8.37 Million | -10.00% |
| 2022 | AU$9.30 Million | -82.68% |
| 2021 | AU$53.72 Million | -64.13% |
| 2020 | AU$149.77 Million | +67.27% |
| 2019 | AU$89.54 Million | +5.77% |
| 2018 | AU$84.65 Million | -44.09% |
| 2017 | AU$151.40 Million | +138.46% |
| 2016 | AU$63.49 Million | +95.00% |
| 2015 | AU$32.56 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Zelira Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.65 Million USD |
| MoneyControl | $4.65 Million USD |
| MarketWatch | $4.65 Million USD |
| marketcap.company | $4.65 Million USD |
| Reuters | $4.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more